MedTrace Logo

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

NCT04555161 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-29

No results posted yet for this study

Summary

This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.

Conditions

Interventions

DEVICE

Aria CV Pulmonary Hypertension System

The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.

Sponsors & Collaborators

  • Aria CV, Inc

    lead INDUSTRY

Principal Investigators

  • Ashwin Ravichandran, M.D. · Ascension Health

  • Jim White, M.D., Ph.D. · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2025-10-31
Completion
2026-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04555161 on ClinicalTrials.gov